What is DaVita's market cap?

DaVita (DVA) has a market capitalization of $15.2B and trades on NYSE.

What is DaVita's revenue and profitability?

DaVita generated $13.8B in trailing twelve-month revenue with net income of $781.4M, representing a net margin of 5.6%, with free cash flow of $1.5B. These figures are based on the Q1 2026 filing.

Who are DaVita's competitors?

DaVita's key competitors include UnitedHealth Group, Outset Medical, Inc. Common Stock, Rockwell Medical, Inc. (DE) Common Stock, and others. These companies compete in similar markets and product categories.

Who does DaVita partner with?

DaVita's notable partners include United States Department of Veterans Affairs, Centers for Medicare & Medicaid Services.

What subsidiaries does DaVita have?

DaVita's subsidiaries include MedSleuth, DaVita Clinical Research, DaVita Venture Group.

Where is DaVita headquartered?

DaVita is headquartered in United States of America and employs approximately 70,000 people. It has been publicly traded since 1995.

DaVita

DVA

DaVita is a leading healthcare provider specializing in comprehensive kidney care and dialysis services for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD).

Market cap

$15.17B+38.8%

Revenue$13.8B+6.7%

Net income$781.4M-9.1%

Free cash flow$1.5B-15.2%

EPS (diluted)$10.71+6.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 5, 2026

Revenue$3.4BBeat by $59.1M EPS$2.87Beat by $0.46

Read the full report

Next report

Aug 4, 2026 (In 6 days)

Revenue estimate$3.5B

EPS estimate$3.88

Financials

Q1 2026

Income statement

See full

Revenue$3.4B+6.0%

Operating income$481.9M+9.8%

Net income$197.5M+21.2%

EPS (diluted)$2.87+43.5%

Balance sheet

See full

Cash & equivalents$726.4M+38.5%

Total debt$13.3B+6.7%

Total equity-$755.5M-183%

Total assets$17.5B+2.2%

Cash flow

See full

Operating cash flow$320.8M+78.2%

CapEx$102.0M-28.8%

Free cash flow$218.8M+495%

Valuation & ratios

Valuation

See full

Market cap$15.17B+38.8%

Enterprise value$27.77B+19.8%

P/E19.4×+6.3×

P/S1.1×+0.3×

Profitability

See full

Operating margin15.1%-0.7pp

Net margin5.6%-1.0pp

FCF margin10.8%-2.8pp

Returns & leverage

See full

Current ratio1.4×+0.2×

Segments

By segment

See full

Other - Ancillary Services$248.2M+18.3%

Competitors

By market cap

UnitedHealth Group$379.28B+48.2%

DaVita$15.2B+38.1%

Option Care Health, Inc.$3.4B-29.7%

Akebia Therapeutics$343.4M-63.6%

PRO

ProKidney Corp.$316.0M-23.1%

InfuSystem Holdings$188.9M+52.6%

Outset Medical, Inc.$80.1M-75.0%

Rockwell Medical$27.6M-21.7%

By revenue growth

UnitedHealth Group+9.7%

DaVita+6.7%

Option Care Health, Inc.+5.9%

InfuSystem Holdings+3.5%

Outset Medical, Inc.+2.0%

By net margin

DaVita5.65%-1.0pp

InfuSystem Holdings5.56%+3.2pp

Option Care Health, Inc.3.68%-0.3pp

UnitedHealth Group2.68%-2.7pp

Outset Medical, Inc.-63.65%+35.1pp

Profile

DaVita is a leading healthcare provider specializing in comprehensive kidney care and dialysis services for patients with chronic kidney disease (CKD) and end-stage kidney disease (ESKD). The company operates a global network of outpatient centers and provides integrated care management, laboratory services, and hospital inpatient treatments. Its core value proposition focuses on improving clinical outcomes and patient quality of life through a patient-centric care model and value-based care arrangements.

Competitive position

DaVita is a leading provider of dialysis services in the U.S. and a global leader in clinical quality, maintaining a significant market share alongside major competitors like Fresenius.

GeographiesUnited States, Brazil, Colombia, Malaysia, Poland, Germany, United Kingdom, Saudi Arabia, China

Customer segmentsPatients, Government agencies, Commercial insurers, Hospitals

Business modelFee-for-service, Value-based care, Risk-based integrated care, Management services

SuppliersMedical equipment manufacturers, Pharmaceutical suppliers, Nephrologists and physician groups, Specialized clinical labor

CustomersMedicare and Medicaid programs, Commercial health insurance plans, Acute care hospitals, ESKD and CKD patients

CountryUnited States of America

Listed1995

Employees70.0K

CEOJavier J. Rodriguez

SectorHealthcare

IndustryMedical - Care Facilities

Websitedavita.com

FilingsSEC EDGAR

Ask your AI about DaVita.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is DaVita's market cap?: DaVita (DVA) has a market capitalization of $15.2B and trades on NYSE.
What is DaVita's revenue and profitability?: DaVita generated $13.8B in trailing twelve-month revenue with net income of $781.4M, representing a net margin of 5.6%, with free cash flow of $1.5B. These figures are based on the Q1 2026 filing.
Who are DaVita's competitors?: DaVita's key competitors include UnitedHealth Group, Outset Medical, Inc. Common Stock, Rockwell Medical, Inc. (DE) Common Stock, and others. These companies compete in similar markets and product categories.
Who does DaVita partner with?: DaVita's notable partners include United States Department of Veterans Affairs, Centers for Medicare & Medicaid Services.
What subsidiaries does DaVita have?: DaVita's subsidiaries include MedSleuth, DaVita Clinical Research, DaVita Venture Group.
Where is DaVita headquartered?: DaVita is headquartered in United States of America and employs approximately 70,000 people. It has been publicly traded since 1995.